RaySearch Laboratories AB (publ) has announced that treatment planning system RayStation®* is now in clinical use with boron neutron capture therapy (BNCT) - along with treatment machine from Sumitomo Heavy Industries, Ltd. (SHI) - at two leading cancer clinics in Japan.
RaySearch announced in 2017 that it had entered into an agreement with Japanese manufacturer SHI regarding treatment planning for BNCT. The accelerator-based BNCT system and dose-calculation program from SHI obtained market clearance in spring 2020.
The advancement of BNCT as a form of radiation therapy is taking place at centers such as Osaka Medical College and Southern Tohoku Hospital. Accelerator-based BNCT is a relatively new method of delivering BNCT and facilitates an emerging hospital-based utilization of the BNCT modality.
Clinicians at Southern Tohoku General Hospital in Koriyama, Fukushima, treated the first patient with the combination of SHI's BNCT treatment delivery equipment and RayStation on May 26, 2020. The clinical start at Osaka Medical College in Osaka followed shortly thereafter. The first clinical application concerns treatment of unresectable recurrent head and neck tumors and is covered by Japanese national health insurance since June 1, 2020.
BNCT uses a two-step process. Firstly, the patient is injected with a tumor-localizing drug containing the non-radioactive isotope boron-10. In the second step, the target area is exposed to a beam of low-energy neutrons, many of which are absorbed by the boron-10. The absorption initiates a reaction in which short-range, high-energy charged particles are emitted. These particles systematically destroy tumor cells with minimal damage to adjacent healthy tissue.
RayStation supports BNCT treatment planning for the SHI system with tools for contouring, image importing, plan creation and evaluation, and reporting.
Johan Löf, founder and CEO, RaySearch, says: "RaySearch exists to further advance cancer treatment through innovative software solutions designed to support cutting-edge medical equipment. Our cooperation with SHI and the resulting clinical use in Japan is a perfect example of how RayStation can support cancer treatment for most modalities and for a wide range of treatment devices".
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare*. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003.
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment.
* Subject to regulatory clearance in some markets.
More information about RaySearch is available at www.raysearchlabs.com
For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)7-066 105 59